AZ bags two extensions in latest CHMP decisions
The Committee also recommended granting a marketing authorisation for La Jolla’s Giapreza, among other decisions.
Read More
Tag: Revolade
Data back first-line use of Novartis’ eltrombopag in SAA
Novartis has announced the publication of data showing high response rates in patients with the rare blood disorder severe aplastic anaemia (SAA) taking its medicine eltrombopag, supporting its first-line use for the condition.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
